Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Útgáfudagur
2017-03
Metadata
Show full item recordCitation
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. 2017, 2 (3):161-176 Lancet Gastroenterol HepatolÚtdráttur
The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of-and expansion on-the 2014 analysis, which reported 80 million (95% CI 64-103) viraemic infections in 2013.We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data.
Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8-1·1) in 2015, corresponding to 71·1 million (62·5-79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively).
The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.
Lu00FDsing
To access publisher's full text version of this article click on the hyperlink belowRights
Archived with thanks to The lancet. Gastroenterology & hepatologyae974a485f413a2113503eed53cd6c53
10.1016/S2468-1253(16)30181-9
Scopus Count
Collections
Related articles
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
- Authors: Polaris Observatory HCV Collaborators.
- Issue date: 2022 May
- Global prevalence of hepatitis C virus in children in 2018: a modelling study.
- Authors: Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, Estes C, Gamkrelidze I, Jerabek K, Ma S, Montoya S, Razavi-Shearer D, Razavi-Shearer K, Robbins-Scott S, Razavi H, El Sayed MH
- Issue date: 2020 Apr
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
- Authors: European Union HCV Collaborators.
- Issue date: 2017 May
- Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study.
- Authors: Dugan E, Blach S, Biondi M, Cai Z, DePaola M, Estes C, Feld J, Gamkrelidze I, Kottilil S, Ma S, Mathur P, Montoya S, Razavi-Shearer D, Razavi-Shearer K, Robbins-Scott S, Schmelzer J, Razavi H
- Issue date: 2021 Mar
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.
- Authors: Polaris Observatory Collaborators.
- Issue date: 2018 Jun